Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Hard Copy Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs Espicom Business Intelligence Ltd, May 2007, Pages: 110   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   Exciting opportunities in this high growth area can be expected over the next 10 years. At least nine significant products will lose patent protection in key markets and this number could increase depending on the outcome of patent challenges. The inhalation and intranasal drugs discussed in this new report had combined sales exceeding US$18 billion in 2006. These drugs are used in the treatment of asthma, COPD, allergic rhinitis, influenza, migraine and osteoporosis, and in general anaesthesia. More importantly, from a generic industry perspective is that at least 9 significant products will lose patent protection in key markets over the next 10 years, and this number could increase depending on the outcome of patent challenges. The generics market is undergoing radical restructuring, with much rationalisation of the corporate landscape. In such a competitive cauldron companies are now seeking not just new opportunities but opportunities which combine good profit levels and a degree of product novelty - both of which are available in the inhalation and nasal spray market. IDENTIFY THE OPPORTUNITIES AND THE COMPANIES INVOLVED This new report provides industry planners, commercial developers and the investment community with a thorough review of the potential for generic inhalation and nasal spray drugs over the next 5 years. Packed with primary source information and original market forecasts, it takes a balanced view of the players and products that will shape this high value market sector. THE REPORT PROVIDES... - Full 5-year product/market forecasts by value to 2011 - Generic market context - Reviews of 18 leading players - Analysis of significant litigation - Patent expiry opportunities to 2016 JUST SOME OF THE QUESTIONS ANSWERED BY THE REPORT: - What are the most promising future product opportunities and when do they lose patent protection? - What drug delivery challenges must companies overcome if they are to really benefit in the marketplace? - What will be the effect on the value of GSK’s blockbusting Advair in 2011 assuming generic competition starts in 2008? - Which therapy areas offer the best potential for ANDA development? Customers who bought this item also bought Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil Injectable Generic Drugs: Prospects and Opportunities to 2010 The Latin American Market for Generic Drugs - A Comparative Study of 7 Key Markets Trends in Generic Drugs and Diabetes Treatments U.S. Generic Pharmaceuticals Outlook Emerging Generic Drug Companies Worldwide 2007 Cancer Stem Cells: Emerging Therapeutic, Diagnostic and Market Opportunities Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster